Chemed Management
Management criteria checks 3/4
Chemed's CEO is Kevin McNamara, appointed in Aug 1994, has a tenure of 30.33 years. total yearly compensation is $12.63M, comprised of 12.7% salary and 87.3% bonuses, including company stock and options. directly owns 0.68% of the company’s shares, worth €50.87M. The average tenure of the management team and the board of directors is 24.6 years and 15.6 years respectively.
Key information
Kevin McNamara
Chief executive officer
US$12.6m
Total compensation
CEO salary percentage | 12.7% |
CEO tenure | 30.3yrs |
CEO ownership | 0.7% |
Management average tenure | 24.6yrs |
Board average tenure | 15.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | US$302m |
Jun 30 2024 | n/a | n/a | US$301m |
Mar 31 2024 | n/a | n/a | US$283m |
Dec 31 2023 | US$13m | US$2m | US$273m |
Sep 30 2023 | n/a | n/a | US$245m |
Jun 30 2023 | n/a | n/a | US$226m |
Mar 31 2023 | n/a | n/a | US$240m |
Dec 31 2022 | US$12m | US$1m | US$250m |
Sep 30 2022 | n/a | n/a | US$262m |
Jun 30 2022 | n/a | n/a | US$277m |
Mar 31 2022 | n/a | n/a | US$267m |
Dec 31 2021 | US$12m | US$1m | US$269m |
Sep 30 2021 | n/a | n/a | US$308m |
Jun 30 2021 | n/a | n/a | US$303m |
Mar 31 2021 | n/a | n/a | US$329m |
Dec 31 2020 | US$12m | US$1m | US$319m |
Sep 30 2020 | n/a | n/a | US$271m |
Jun 30 2020 | n/a | n/a | US$263m |
Mar 31 2020 | n/a | n/a | US$231m |
Dec 31 2019 | US$10m | US$1m | US$220m |
Sep 30 2019 | n/a | n/a | US$209m |
Jun 30 2019 | n/a | n/a | US$201m |
Mar 31 2019 | n/a | n/a | US$205m |
Dec 31 2018 | US$9m | US$1m | US$206m |
Sep 30 2018 | n/a | n/a | US$206m |
Jun 30 2018 | n/a | n/a | US$190m |
Mar 31 2018 | n/a | n/a | US$113m |
Dec 31 2017 | US$8m | US$1m | US$98m |
Compensation vs Market: Kevin's total compensation ($USD12.63M) is above average for companies of similar size in the German market ($USD3.33M).
Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.
CEO
Kevin McNamara (70 yo)
30.3yrs
Tenure
US$12,625,106
Compensation
Mr. Kevin J. McNamara has been the Chief Executive Officer of Chemed Corporation since May 2001 and has been its President since August 2, 1994. Previously, Mr. McNamara served as an Executive Vice Preside...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, President & Director | 30.3yrs | US$12.63m | 0.68% € 50.9m | |
VP, Controller | 12.6yrs | US$2.93m | 0.025% € 1.9m | |
Executive Vice President | 24.6yrs | US$3.37m | 0.12% € 9.1m | |
VP & Director | 36.8yrs | no data | 0.56% € 41.9m | |
Executive Vice President | 8.5yrs | US$4.71m | 0.041% € 3.1m | |
VP, Chief Administrative Officer & Secretary | 30.1yrs | no data | no data | |
Director of Investor Relations | no data | no data | no data | |
VP, Secretary & Chief Legal Officer | 4.3yrs | no data | 0.010% € 766.6k | |
VP & Chief Strategy Officer | no data | no data | no data |
24.6yrs
Average Tenure
52.5yo
Average Age
Experienced Management: CXM's management team is seasoned and experienced (24.6 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, President & Director | 37.9yrs | US$12.63m | 0.68% € 50.9m | |
VP & Director | 39.9yrs | no data | 0.56% € 41.9m | |
Independent Director | 15.6yrs | US$278.27k | 0.040% € 3.0m | |
Director Emeritus | 15.6yrs | US$157.02k | no data | |
Independent Director | 28.9yrs | US$308.60k | 0.022% € 1.6m | |
Independent Chairman | 29.9yrs | US$453.15k | 0.023% € 1.7m | |
Independent Director | 16.6yrs | US$272.77k | 0.038% € 2.9m | |
Independent Director | 4.6yrs | US$279.43k | 0.014% € 1.1m | |
Independent Director | 4.6yrs | US$278.27k | 0.0093% € 694.2k | |
Independent Director | 2.3yrs | US$278.27k | 0.0044% € 326.2k | |
Independent Director | 1.6yrs | US$238.52k | 0.0039% € 288.9k |
15.6yrs
Average Tenure
70yo
Average Age
Experienced Board: CXM's board of directors are seasoned and experienced ( 15.6 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/25 08:34 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Chemed Corporation is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Ishan Majumdar | Baptista Research |
Adam Feinstein | Barclays |
Joanna Sylvia Gajuk | BofA Global Research |